Quanterix’ Simoa Technology Sets New Standard in Protein Detection
New research published in Lab on a Chip demonstrates 100x sensitivity improvement on Simoa; marks significant advancement in sensitivity for industry leading detection platform
“We believe that this work is highly relevant to those in the biomedical industries striving for sensitive detection of protein biomarkers, including researchers developing novel therapeutics and next-generation diagnostics, and clinicians performing cutting-edge translational biomarker research,” said Duffy. “We also believe that the immunoassays developed using this advance in Simoa are the most sensitive reported to date, by enabling detection at never-before-seen sub-attomolar concentrations. Greater sensitivity of protein measurements, when combined with high specificity, can enable greater diversity in the measurement of proteins found and the samples paving the way for significant discoveries across a range of diseases and health conditions.”
The paper also describes a novel method called magnetic-meniscus sweeping (MMS) that increased by 10-fold the number of beads loaded into arrays of microwells in the Simoa disk. Improved optics and image analysis algorithms also contributed to improved sensitivity.
The 100x advance solidifies Simoa’s leadership position as an enabling technology in new types of measurements of proteins. For example, detection of neurological biomarkers in plasma and serum, offering the potential of “blood tests for the brain” for the first time. In particular, greater sensitivity allows the detection of low abundance post-translational modifications of proteins, such as the detection of abnormal accumulation of a phosphorylated tau protein, the presence of which is consistent with the neurodegenerative changes associated with Alzheimer’s disease. Improved sensitivity also unlocks new capabilities for the detection of inflammatory cytokines in the blood of healthy and diseased patients, and the detection of proteins important in the early and accurate detection of infectious agents.
“Achieving this important innovation goal is key for
The greater sensitivity carries particular significance in the fight against COVID-19 by powering greater detection of proteins central to infectious diseases, namely, viral antigens, and the antibodies and cytokines that are generated during host response. For example, improved sensitivity will further improve Simoa’s ability to measure cytokine concentrations associated with cytokine release, a severe immune response to the virus. European researchers in the
*Manuscript Title: “Digital Enzyme-Linked Immunosorbent Assays with Sub-Attomolar Detection Limits Based on Low Numbers of Capture Beads Combined with High Efficiency Bead Analysis.”
This technology is patent pending.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the
Investor Relations Contact: